Daridorexant for treating long-term insomnia (TA922)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 January 2022
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 August 2021Published: 26 March 2008
Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2004
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eszopiclone for treating insomnia TS ID 12020Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC